Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
ARID1A, a subunit of the SWI/SNF complex, is among the most frequently mutated genes across cancer types. ARID1A is mutated in more than 50% of ovarian clear cell carcinomas (OCCCs), diseases that have no effective therapy. Here, we show that ARID1A mutation confers sensitivity to pan-HDAC inhibitors such as SAHA in ovarian cancers. This correlated with enhanced growth suppression induced by the inhibition of HDAC2 activity in ARID1A-mutated cells. HDAC2 interacts with EZH2 in an ARID1A status-dependent manner. HDAC2 functions as a co-repressor of EZH2 to suppress the expression of EZH2/ARID1A target tumor suppressor genes such as PIK3IP1 to inhibit proliferation and promote apoptosis. SAHA reduced the growth and ascites of the ARID1A-inactivated OCCCs in both orthotopic and genetic mouse models. This correlated with a significant improvement of survival of mice bearing ARID1A-mutated OCCCs. These findings provided preclinical rationales for repurposing FDA-approved pan-HDAC inhibitors for treating ARID1A-mutated cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096 · cited 1×
“For example, saturation analysis of The Cancer Genome Atlas (TCGA) cancer mutational profile finds that the ARID1A subunit of the SWI/SNF complex is among the genes that show the highest mutation rates across multiple cancer types (Lawrence et al., 2014).”
BackgroundARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712 · cited 3×
“ARID1A mutations observed in ovarian cancer are frame-shift or nonsense mutations that result in the loss of ARID1A protein expression (Jones et al., 2010; Wiegand et al., 2010).”
BackgroundSelf-citationNew and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404 · cited 2×
“Histone deacetylases (HDACs) are established targets against cancers (West and Johnstone, 2014).”
BackgroundFDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365 · cited 2×
“Thus, we explored the therapeutic potential for SAHA, an FDA-approved pan-HDAC inhibitor that is suitable for in vivo animal studies (Mann et al., 2007), in ARID1A-mutated ovarian cancers of preclinical models.”
BackgroundHDAC2 promotes loss of primary cilia in pancreatic ductal adenocarcinoma
Kobayashi, T., Nakazono, K., Tokuda, M., Mashima, Y., Dynlacht, B. D., & Itoh, H. (2017) · The EMBO Reports · doi:10.15252/embr.201541922 · Cited by 75 · cited 1×
“The observed growth inhibition induced by HDAC2 knockdown can be rescued by a short hairpin RNA (shRNA)-resistant wild-type HDAC2, but not a mutant HDAC2 H142A that is deficient for its catalytic activity (Figures 1F, 1G, S1W, and S1X) (Kobayashi et al., 2017).”
Background
Cited by
The SWI/SNF complex in cancer — biology, biomarkers and therapy
Mittal, P., & Roberts, C. W. M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0357-3 · Cited by 690
Epigenetic mechanisms in breast cancer therapy and resistance
Garcia-Martinez, L., Zhang, Y., Nakata, Y., Chan, H. L., & Morey, L. (2021) · Nature Communications · doi:10.1038/s41467-021-22024-3 · Cited by 458
Milazzo, G., Mercatelli, D., Di Muzio, G., Triboli, L., De Rosa, P., Perini, G., & Giorgi, F. M. (2020) · Genes · doi:10.3390/genes11050556 · Cited by 423
The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
Li, G., Tian, Y., & Zhu, W.-G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.576946 · Cited by 352
Epigenetic therapy for ovarian cancer: promise and progress
Moufarrij, S., Dandapani, M., Arthofer, E., Gomez, S., Srivastava, A., Lopez-Acevedo, M., Villagra, A., & Chiappinelli, K. B. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0602-0 · Cited by 319
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
Xiong, J., Cui, B.-W., Wang, N., Dai, Y.-T., Zhang, H., Wang, C.-F., Zhong, H.-J., Cheng, S., Ou-Yang, B.-S., Hu, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.02.005 · Cited by 233
Targeting ARID1A mutations in cancer
Mullen, J., Kato, S., Sicklick, J. K., & Kurzrock, R. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102287 · Cited by 186
Lo, Y.-H., Kolahi, K. S., Du, Y., Chang, C.-Y., Krokhotin, A., Nair, A., Sobba, W. D., Karlsson, K., Jones, S. J., Longacre, T. A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1109 · Cited by 174
HDACs and the epigenetic plasticity of cancer cells: target the complexity
Brancolini, C., Gagliano, T., & Minisini, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108190 · Cited by 55
Metadata
- Authors
- Fukumoto, T., Park, P. H., Wu, S., Fatkhutdinov, N., Karakashev, S., Nacarelli, T., Kossenkov, A. V., Speicher, D. W., Jean, S., Zhang, L., Wang, T.-L., Shih, I.-M., Conejo-Garcia, J. R., Bitler, B. G., & Zhang, R.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 22
- Issue
- 13
- Pages
- 3393-3400
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2795189660
- Cited by
- 103
- References
- 5
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.